Company Overview
Intensity Therapeutics, Inc. operates as a late-stage clinical biotechnology company focused on developing treatments for the regional and systemic nature of cancer within the United States. The firm's primary business activity centers on the provision of therapeutic solutions, with its lead product candidate, INT230-6, currently advancing through Phase 3 clinical studies for the treatment of soft tissue sarcoma. This entity functions within the healthcare sector, specifically inside the biotechnology industry, where capital-intensive research and development are standard operating procedures for advancing novel compounds. The company maintains a market capitalization of $15.28M and employs 5 individuals, reflecting the typical scale of a pre-revenue or late-stage development biotech firm. The combination of a market cap under $20 million and zero reported revenue indicates that the company is in a capital deployment phase rather than a commercial revenue generation phase, relying entirely on external financing to fund its clinical trials and operational expenses.
Financial Health
The company reports N/A for revenue (TTM) and N/A for EBITDA, while its net income (TTM) stands at a significant loss of $-11,736,000. The absence of revenue paired with a net income loss of $-11.736 million reveals a cost structure where operating expenses vastly exceed any potential earnings, a common characteristic of biotechnology firms in late-stage development. Free cash flow is reported at $-5,259,875, which indicates that the company is burning cash at a rate of approximately $5.26 million annually, thereby reducing its financial flexibility and increasing reliance on future fundraising events. The margins profile shows a gross margin of 0.0%, an operating margin of 0.0%, and a profit margin of 0.0%, all of which signify that the company has not yet achieved profitability from its operations. Regarding balance sheet leverage, the company holds $7.07M in cash against $118,000 in debt, resulting in a debt-to-equity ratio of 1.63, which suggests a leveraged position relative to equity but is partially offset by substantial cash reserves. The current ratio is 3.60, indicating that the company possesses $3.60 in current assets for every $1.00 in current liabilities, which points to strong short-term liquidity despite the lack of commercial revenue. Return on Equity is -234.7% and Return on Assets is -101.7%, metrics that reveal management is currently generating negative returns on the capital invested, a standard expectation for biotech entities that have not yet commercialized their pipeline products.
Valuation Assessment
The valuation metrics present a unique profile for a loss-making entity, with a trailing P/E (TTM) listed as N/A and a forward P/E of -1.45. The disparity between a non-existent trailing P/E and a negative forward P/E implies that the market is pricing in future earnings potential that does not yet exist, as the company is currently unprofitable. The price-to-book ratio is 1.64, which indicates that the market is valuing the company at 1.64 times its book value, suggesting a premium over the net asset value of the firm. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are both N/A, suggesting that traditional multiple-based comparisons with profitable peers are not applicable due to the lack of sales and earnings data. The stock's price has exhibited significant volatility over the last year, trading between a 52-week high of $54.50 and a 52-week low of $4.62. To determine the current price position relative to this range, one must observe that the stock is trading at 91.56% below the 52-week high of $54.50 and at 109.72% above the 52-week low of $4.62. The beta value is 4.28, which means the stock price is expected to fluctuate 4.28 times as much as the broader market, highlighting extreme sensitivity to market movements and investor sentiment.
Growth & Income
Revenue growth (YoY) and earnings growth (YoY) are both listed as N/A, preventing a direct comparison of growth rates between earnings and revenue. Because the company has not yet generated commercial revenue, it is impossible to determine if earnings are growing faster or slower than revenue in a traditional sense, as both figures are effectively zero or non-existent. Regarding income distribution, the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Since the payout ratio is 0.0%, the company is not distributing any earnings to shareholders, which is consistent with its strategy of reinvesting all available resources, including its $7.07M cash balance, into research and development rather than paying dividends. The overall growth and income profile is characterized by a complete absence of current commercial growth metrics and dividend income, positioning the firm purely as a capital appreciation play dependent on the successful progression of its clinical pipeline.